Neurocrine Completes Acquisition of Soleno
Neurocrine Biosciences (NBIX) announced the completion of its acquisition of Soleno Therapeutics (SLNO), strengthening the company's leadership in endocrinology and rare disease. As of May 18, Soleno's common stock will no longer be listed or traded on the Nasdaq Capital Market.
